Press release
Osteoarthritis Pipeline 2024 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma
Request a sample and discover the recent advances in Osteoarthritis treatment drugs @ Osteoarthritis Pipeline Outlook [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Osteoarthritis Pipeline Report
* June 2024:- New Approaches to Neuroblastoma Therapy Consortium- Phase II Study of Ex-Vivo Expanded Allogeneic Universal Donor TGFi NK Cell Infusions in Combination With Temozolomide, Irinotecan, Dinutuximab, and Sargramostim in Patients With Relapsed or Refractory Neuroblastoma The STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial. This is a phase II study looking at patient response to treatment with the combination dinutuximab, temozolomide, irinotecan, and GM-CSF.
* DelveInsight's Osteoarthritis pipeline report depicts a robust space with 130+ active players working to develop 130+ pipeline therapies for Osteoarthritis treatment.
* The leading Osteoarthritis Companies working in the market include Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
* Promising Osteoarthritis Therapies in the various stages of development include E1K 1,200 joint, MK0663, etoricoxib, Chondroitin 4&6 sulfate (Condrosulf), and others.
Find out more about Osteoarthritis treatment drugs @ Drugs for Osteoarthritis Treatment [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Osteoarthritis Emerging Drugs Profile
* Lorecivivint: Biosplice Therapeutics
* CYP 004: Cynata Therapeutics
* JTA-004: Bone Therapeutics
* SMUP-IA-01: Medipost
* TTAX03: Tissue Tech
Osteoarthritis Therapeutics Assessment
There are approx. 130+ key companies which are developing the Osteoarthritis emerging therapies. The Osteoarthritis companies which have their Osteoarthritis drug candidates in the most advanced stage, i.e phase III include Biosplice Therapeutics.
DelveInsight's Osteoarthritis pipeline report covers around 130+ products under different phases of Osteoarthritis clinical trials development like
* Late stage products (Phase III)
* Mid-stage products (Phase II)
* Early-stage product (Phase I) along with the details of
* Pre-clinical and Discovery stage candidates
* Discontinued & Inactive candidates
Learn more about the emerging Osteoarthritis pipeline therapies @ Osteoarthritis Clinical Trials [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Osteoarthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
* Oral
* Intravenous
* Subcutaneous
Osteoarthritis Products have been categorized under various Molecule types such as
* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy
Osteoarthritis Companies
Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
Dive deep into rich insights for new drugs for Osteoarthritis Treatment, visit @ New Osteoarthritis Drugs [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Osteoarthritis Pipeline Report
* Coverage- Global
* Osteoarthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Osteoarthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
* Osteoarthritis Companies- Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma, Taiwan Bio Therapeutics, OliPass Corporation, Bioventus, Medipost, Moebius Medical, ReqMed, TissueTech, Novartis, AstraZeneca, Biosplice Therapeutics, Cynata Therapeutics, Bone Therapeutics S.A, Regeneron Pharmaceuticals, Techfields Pharma, Ampio Pharmaceuticals, Taiwan Liposomal Company, K-STEMCELL, Stempeutics, Levolta Pharmaceuticals, and others.
* Osteoarthritis Therapies- E1K 1,200 /joint, MK0663, etoricoxib, Chondroitin 4&6 sulfate (Condrosulf), and others.
For further information on the Osteoarthritis Pipeline Therapeutics, reach out @ Osteoarthritis Treatment Drugs [https://www.delveinsight.com/sample-request/osteoarthritis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Osteoarthritis: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Osteoarthritis- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Lorecivivint: Biosplice Therapeutics
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* TTAX03: Tissue Tech
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* GLPG-0555: Gilead Sciences
* Drug profiles in the detailed report.....
* Preclinical Stage Products
* Protego-PD: Plakous Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Osteoarthritis Key Companies
* Osteoarthritis Key Products
* Osteoarthritis- Unmet Needs
* Osteoarthritis- Market Drivers and Barriers
* Osteoarthritis- Future Perspectives and Conclusion
* Osteoarthritis Analyst Views
* Osteoarthritis Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=osteoarthritis-pipeline-2024-biosplice-therapeutics-gilead-sciences-flexion-therapeutics-glaxosmithkline-levicept-arthrogen-personalized-stem-cells-peptinov-asahi-kasei-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Osteoarthritis Pipeline 2024 | Biosplice Therapeutics, Gilead Sciences, Flexion Therapeutics, GlaxoSmithKline, Levicept, Arthrogen, Personalized Stem Cells, Peptinov, Asahi Kasei Pharma here
News-ID: 3577571 • Views: …
More Releases from ABNewswire
Best Tax Software in the UK | Pie Redefines Simplicity in Digital Tax Filing
Pie has been named among the best tax software in the UK, recognised for transforming the way taxpayers file with HMRC. Combining ease of use, accuracy, and innovation, Pie gives individuals and small businesses a smarter way to manage their taxes digitally.
LONDON, United Kingdom - 3 Nov, 2025 - In a year that's redefining digital finance, Pie has been recognised as one of the best tax software solutions in the…
From Boredom to Connection: Thundr Makes Random Video Chatting Surprisingly Fun
Image: https://www.abnewswire.com/upload/2025/11/2e6c9d56f2e3bc45a33f5f8bd0a8eaec.jpg
The Magic of Talking to Strangers
Think about the last time you had an unexpected conversation - maybe on a train, in a cafe, or waiting in a queue.For a few moments, you were just two people sharing stories, laughing, or seeing life from a new angle.
That's the spirit behind random video chat [https://thundr.com] - a digital doorway to those spontaneous, human moments that remind us how connected the world…
Still Paddling Out: How One Lifelong Beach Bum Turned His Wanderlust into a Bran …
ChasingVance Inc, founded by a 60-year-old surf enthusiast, transforms decades of beach culture wisdom into a thriving apparel brand for modern nomads and ocean lovers. The company celebrates its successful establishment in the travel and surf apparel market, proving that entrepreneurial dreams have no expiration date.
The surf breaks at dawn witness a familiar silhouette paddling out, just as they have for decades. But this isn't just another morning session for…
Sacred Skin Therapeutics Revolutionizes Autoimmune Skincare with Sea Moss Formul …
A lupus warrior's personal struggle leads to Sacred Skin Therapeutics, the first full-regimen skincare line exclusively for autoimmune and sensitive skin conditions. The brand combines sea moss with botanical actives in clean-label, small-batch formulations, addressing the needs of those with lupus, eczema, psoriasis, and other conditions.
The skincare industry witnesses a paradigm shift as Sacred Skin Therapeutics launches with an unprecedented focus on autoimmune-afflicted skin, introducing formulations that deliver visible improvements…
More Releases for Osteoarthritis
Osteoarthritis Market Massive Growth opportunity Ahead
Introduction
Osteoarthritis (OA), the most common form of arthritis, remains a significant global health burden, causing pain, mobility limitations, and reduced quality of life for millions. Driven by an aging population, lifestyle-related factors like obesity, and a growing focus on musculoskeletal health, the osteoarthritis market is witnessing notable transformation.
According to Exactitude Consultancy, the global osteoarthritis market was valued at USD 14 billion in 2024 and is projected to reach USD 22…
Rising Sports Injuries Fuel Growth In Osteoarthritis Therapeutics Market: The Dr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Osteoarthritis Therapeutics Market Size Growth Forecast: What to Expect by 2025?
In recent times, the osteoarthritis therapeutics market has seen substantial growth. The market size was $8.17 billion in 2024 and is projected to rise to $8.87 billion in 2025, reflecting an annual compound growth rate (CAGR) of 8.6%.…
Osteoarthritis Treatment Market Trends and Forecast 2034
On March 20, 2025, Exactitude Consultancy., Ltd. announces the release of the report "Global Osteoarthritis Treatment Market 2025 by Manufacturers, Regions, Type and Application, Forecast to 2034". The report is a detailed and comprehensive analysis presented by region and country, type and application. As the market is constantly changing, the report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across…
Osteoarthritis Treatment Market
Introduction
Osteoarthritis (OA) is the most common form of arthritis, affecting millions worldwide. It is a degenerative joint disease that primarily impacts the cartilage and causes pain, stiffness, and reduced mobility. The growing prevalence of osteoarthritis, especially among the aging population, has created a significant demand for treatment options. The osteoarthritis treatment market includes various therapeutic approaches, such as medications, physical therapies, and surgical procedures, designed to manage the symptoms and…
Osteoarthritis Therapeutics Market - Finding Freedom from Osteoarthritis: Discov …
Newark, New Castle, USA: The "Osteoarthritis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Osteoarthritis Therapeutics Market: https://www.growthplusreports.com/report/osteoarthritis-therapeutics-market/7779
This latest report researches the industry structure, sales, revenue,…
Osteoarthritis Therapeutics Market: Rising Obese and Geriatric Populations to In …
Industry is experiencing significant growth due to the rapid growth in the geriatric and obese population and the associated increase in the prevalence of osteoarthritis disease. Risk of adverse cardiovascular events associated with the use of NSAIDs in osteoarthritis treatment is likely to hamper the growth of the market.
What the Osteoarthritis Therapeutics Market Looks Like?
The osteoarthritis therapeutics market is projected to reach USD 10.1 billion by 2024 from USD 6.8…
